RxDoctor Payments Data

Linda Rickman, MD

Internal Medicine · Bloomfield, CTNPI 1093789745

Payments from drug & device makers

$3,250in general payments, 2019–2025

Across 30 payments — averaging $108.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Eli Lilly$1K
  • Exact Sciences$62
  • AstraZeneca$40
  • Novo Nordisk$36
  • Lilly USA, LLC$32
  • plus $71 from 4 others
$50in research payments, 2019–2025

Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$50

What the payments were for

  • Travel & lodging$2,60780%
  • Food & beverage$64320%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,250 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$40,749
Medicare patients
109
Services billed
341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$43,101
EliquisApixaban36$30,969
OzempicSemaglutide14$13,537
FarxigaDapagliflozin Propanediol11$12,376
MounjaroTirzepatide12$12,165
Rosuvastatin Calcium111$1,317
SynthroidLevothyroxine Sodium11$875
Ipratropium Bromide31$872
Gabapentin77$867
Risedronate Sodium14$757
Metoprolol Succinate80$737
Pantoprazole Sodium67$724
Amlodipine Besylate156$712
Levothyroxine Sodium80$708
Valsartan30$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$43,10144 claims
Novo NordiskOzempic$36$13,53714 claims
AstraZenecaFarxiga$40$12,37611 claims
Lilly USA, LLCMounjaro$32$12,16512 claims
AbbVieSynthroid$21$87511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →